Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (101-110 of 284) with videos related to

Pageof 29
Sort By:
Molecular Cancer Therapeutics|March 31, 2021
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICCHiroyuki Arai, Shu Cao, Francesca Battaglin, et al.
ESMO Open|December 2, 2020
Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology AssociationLisa Salvatore, Marco Imperatori, Ermenegildo Arnoldi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trialsAlessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, et al.
Plos One|September 24, 2020
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancerYuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trialsJingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Molecular Cancer Therapeutics|July 25, 2015
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal CancerSebastian Stintzing, Wu Zhang, Volker Heinemann, et al.
The Oncologist|March 19, 2022
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino StudyGiovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, et al.
The Journal of Pathology|January 9, 2025
Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcomeNicholas Trahearn, Chirine Sakr, Abhirup Banerjee, et al.
British Journal of Cancer|January 13, 2017
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancerFederica Marmorino, Lisa Salvatore, Cecilia Barbara, et al.
Pageof 29

Showing results (101-110 of 284) with videos related to

Sort By:
Pageof 29
Molecular Cancer Therapeutics|March 31, 2021
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICCHiroyuki Arai, Shu Cao, Francesca Battaglin, et al.
ESMO Open|December 2, 2020
Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology AssociationLisa Salvatore, Marco Imperatori, Ermenegildo Arnoldi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trialsAlessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, et al.
Plos One|September 24, 2020
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancerYuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trialsJingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 19, 2024
Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluationRomain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Molecular Cancer Therapeutics|July 25, 2015
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal CancerSebastian Stintzing, Wu Zhang, Volker Heinemann, et al.
The Oncologist|March 19, 2022
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino StudyGiovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, et al.
The Journal of Pathology|January 9, 2025
Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcomeNicholas Trahearn, Chirine Sakr, Abhirup Banerjee, et al.
British Journal of Cancer|January 13, 2017
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancerFederica Marmorino, Lisa Salvatore, Cecilia Barbara, et al.
Pageof 29